UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination

British journal of haematology, 2023-09, Vol.202 (6), p.1091-1103

2023

Volltextzugriff (PDF)

PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Clinical cancer research, 2024-01, Vol.30 (1), p.139-149

2024

Volltextzugriff (PDF)

Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial

British journal of haematology, 2021-03, Vol.192 (6), p.1015-1019

2021

Volltextzugriff (PDF)

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

Leukemia & lymphoma, 2019-09, Vol.60 (11), p.2705-2711

2019

Volltextzugriff (PDF)

Ofatumumab is a feasible alternative anti‐CD20 therapy in patients intolerant of rituximab

British journal of haematology, 2019-02, Vol.184 (3), p.462-465

2019

Volltextzugriff (PDF)

Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy

AIDS (London), 2015-05, Vol.29 (8), p.903-910

2015

Volltextzugriff (PDF)

Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre

European journal of haematology, 2021-02, Vol.106 (2), p.267-272

2021

Volltextzugriff (PDF)

Results of a multicentre UK‐wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting

British journal of haematology, 2017-11, Vol.179 (3), p.471-479

2017

Volltextzugriff (PDF)

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial

The Lancet. Haematology, 2018-05, Vol.5 (5), p.e190-e200

2018

Volltextzugriff (PDF)

Results of a multicentre UK‐wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma

British journal of haematology, 2018-05, Vol.181 (4), p.555-559

2018

Volltextzugriff (PDF)

Response to ‘Impact of immunosuppression on mortality in critically ill COVID‐19 patients’

British journal of haematology, 2020-11, Vol.191 (3), p.505-506

2020

Volltextzugriff (PDF)

R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial

Annals of hematology, 2020, Vol.99 (1), p.105-112

2020

Volltextzugriff (PDF)

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study

EClinicalMedicine, 2023-02, Vol.56, p.101779-101779, Article 101779

2023

Volltextzugriff (PDF)

Central nervous system prophylaxis in patients with diffuse large B cell lymphoma, are we treating ourselves? A response to the recent BCSH Guideline – response to Griffin et al

British journal of haematology, 2014-11, Vol.167 (4), p.579-580

2014

Volltextzugriff (PDF)

Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials

British journal of haematology, 2019-04, Vol.185 (2), p.344-347

2019

Volltextzugriff (PDF)

Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?

The cancer journal (Sudbury, Mass.), 2012-09, Vol.18 (5), p.390-395

2012

Volltextzugriff (PDF)

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Blood advances, 2024-01, Vol.8 (1), p.93-98

2024

Volltextzugriff (PDF)

Autologous stem cell transplantation outcomes in elderly patients with B cell Non‐Hodgkin Lymphoma

British journal of haematology, 2015-10, Vol.171 (2), p.197-204

2015

Volltextzugriff (PDF)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value

Core evidence, 2007-11, Vol.2 (2), p.121-129

Ardeshna, Kirit M

2007

Volltextzugriff (PDF)

Whole Body 3.0 T Magnetic Resonance Imaging in Lymphomas: Comparison of Different Sequence Combinations for Staging Hodgkin's and Diffuse Large B Cell Lymphomas

Journal of personalized medicine, 2020-12, Vol.10 (4), p.284

2020

Volltextzugriff (PDF)

P1132: LONG‐TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS‐2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e402511c-n/a

2023

Volltextzugriff (PDF)

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

Blood advances, 2022-08, Vol.6 (16), p.4736-4739

2022

Volltextzugriff (PDF)

Neurolymphomatosis in a patient with lymphoblastic lymphoma

British journal of haematology, 2012-03, Vol.156 (6), p.691-691

2012

Volltextzugriff (PDF)

Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience

Leukemia & lymphoma, 2012-12, Vol.53 (12), p.2397-2404

2012

Volltextzugriff (PDF)

26 – 50 von 131

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(131)
Mit Volltextzugriff
(119)

Publikationsform

Artikel
(131)

Sprache

Englisch
(131)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(57)
Science & Technology
(57)
Hematology
(44)
Humans
(43)
Female
(28)
Adult
(27)
Aged
(26)
Middle Aged
(26)
Male
(25)
Lymphoma
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Oncology
(16)
Treatment Outcome
(16)
Young Adult
(15)
Aged, 80 And Over
(14)
Biological And Medical Sciences
(14)
Medical Sciences
(12)
Rituximab
(12)
Chemotherapy
(11)
Hematologic And Hematopoietic Diseases
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination

PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

Ofatumumab is a feasible alternative anti‐CD20 therapy in patients intolerant of rituximab

Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy

Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

Results of a multicentre UK‐wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial

Results of a multicentre UK‐wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma

Response to ‘Impact of immunosuppression on mortality in critically ill COVID‐19 patients’

R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study

Central nervous system prophylaxis in patients with diffuse large B cell lymphoma, are we treating ourselves? A response to the recent BCSH Guideline – response to Griffin et al

Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials

Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Autologous stem cell transplantation outcomes in elderly patients with B cell Non‐Hodgkin Lymphoma

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value

Whole Body 3.0 T Magnetic Resonance Imaging in Lymphomas: Comparison of Different Sequence Combinations for Staging Hodgkin's and Diffuse Large B Cell Lymphomas

P1132: LONG‐TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS‐2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

Neurolymphomatosis in a patient with lymphoblastic lymphoma

Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience

Suchergebnisse filtern